Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy with or without MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer
2021-005458-27Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of mk-4830 in High-Grade Serous Ovarian Cancer (HGSOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA). Started Feb 2022; status: active.
02
Drugs
mk-4830
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-005458-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005458-27.